A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Clinical trial NCT05443724 · COMPLETED
Trial details
- NCT number
- NCT05443724
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-02
- Primary completion
- 2025-06-25
- Enrollment
- 700
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.